Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina's Q3 Earnings Coming Up: Time to Buy, Sell or Hold the Stock?
In the third quarter of 2024, ILMN is likely to have benefited from the significant step-up in consumables with growing customer activity on NovaSeq X.
ILMN Stock Trading Near 52-Week High: Should You Buy, Sell or Hold?
Reaching a new one-year high, Illumina remains in investors' sight owing to its strong strategic execution and positive growth outlook.
Illumina launches compact, low-cost gene sequencing devices
Medical equipment maker Illumina on Wednesday announced its new series of smaller, low-cost benchtop gene sequencers, a move that will make sequencing accessible to more research and testing labs.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Revisiting Illumina
Illumina's stock has rebounded 25% since October 2023, despite underwhelming revenue growth and challenges with the NovaSeq X platform and macro headwinds. The company faces issues with the adoption of NovaSeq X, and increased complexity and costs in data processing. Illumina's scalable business model and high-margin consumable revenues offer significant upside, with potential for substantial margin expansion and EPS improvement by 2027.
Illumina Inc (ILMN) Trading 5.9% Higher on Oct 2
Shares of Illumina Inc (ILMN, Financial) surged 5.90% in mid-day trading on Oct 2. The stock reached an intraday high of $136.82, before settling at $136.59, up from its previous close of $128.98.
GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success
GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's Q2 2024 operational loss was $1.64 billion, primarily due to non-cash goodwill and intangible impairments. GRAIL's restructuring plan aims to cut costs, focus on Galleri sales, and extend its cash runway to 2028, supported by Illumina's continued involvement.
Bull of the Day: Illumina (ILMN)
Big jump after earnings led by a pullback, could be an opportunity here.
EU top court backs Illumina fight against EU probe into Grail deal
Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.
ILMN's TSO Comprehensive IVD Test Secures FDA Approval as CDx
Illumina's cancer biomarker test, TSO Comprehensive, gets approved by the FDA for use as CDx to match patients with targeted therapies.
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
Investors need to pay close attention to Illumina (ILMN) stock based on the movements in the options market lately.
